ReviewCureus2026
Optimising Non-operative Management of Inoperable Malignant Bowel Obstruction: A Clinical Review for Surgical Practice.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inoperable malignant bowel obstruction (MBO) is a frequent and distressing complication of advanced intra-abdominal malignancy, particularly colorectal and ovarian cancer, and is associated with substantial morbidity and limited survival. Management is primarily palliative, with emphasis on symptom control rather than disease modification. For the practising surgeon, MBO represents a common clinical scenario requiring structured non-operative decision-making. This structured narrative review synthesises current evidence on non-operative management strategies for inoperable MBO, based on a systematic literature search. Interventions evaluated include pharmacological therapies, combination regimens, and selected adjunctive measures. Somatostatin analogues, particularly octreotide, demonstrate the most consistent benefit in reducing gastrointestinal secretions and vomiting. Corticosteroids and antiemetics provide adjunctive symptom control, while combination regimens appear to offer enhanced efficacy compared with monotherapy, although supporting evidence remains limited. The available literature is heterogeneous, with relatively few high-quality randomised studies and limited standardisation of outcome measures. Consequently, clinical practice is largely guided by symptom-driven, individualised approaches. Future research should prioritise well-designed multicentre trials, standardised treatment protocols, and incorporation of patient-reported outcomes to strengthen the evidence base and inform clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.